This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
Data availability
Data are available on reasonable request.
References
Beck DB, Ferrada MA, Sikora KA, Ombrello AK, Collins JC, Pei W, et al. Somatic Mutations in UBA1 and severe adult-onset autoinflammatory disease. N Engl J Med. 2020;383:2628–38.
Beck DB, Bodian DL, Shah V, Mirshahi UL, Kim J, Ding Y, et al. Estimated prevalence and clinical manifestations of UBA1 variants associated with VEXAS Syndrome in a clinical population. JAMA. 2023;329:318–24.
Georgin-Lavialle S, Terrier B, Guedon AF, Heiblig M, Comont T, Lazaro E, et al. Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients. Br J Dermatol. 2022;186:564–74.
Gutierrez-Rodrigues F, Kusne Y, Fernandez J, Lasho TL, Shalhoub RN, Ma X, et al. Spectrum of clonal hematopoiesis in VEXAS syndrome. Blood 2023: blood.2022018774.
Mekinian AM, Georgin-Lavaille S, Ferrada MA, Savic S, Koster MJ, Kosmider O et al. American College of Rheumatology Guidance Statement for Diagnosis and Management of VEXAS Developed by the International VEXAS Working Group Expert Panel. Arthritis Rheumatol. 2025. https://doi.org/10.1002/art.43287.
Sirenko M, Bernard E, Creignou M, Domenico D, Farina A, Arango Ossa JE et al. Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes. Blood 2024. blood.2023023723.
Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022;36:1703–19.
Jachiet V, Kosmider O, Beydon M, Hadjadj J, Zhao L-P, Grobost V et al. Efficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from the FRENVEX group. Blood 2025: blood.2024028133.
Gurnari C, Koster L, Baaij LGA, Heiblig M, Yakoub-Agha I, Collin M et al. Allogeneic Hematopoietic Cell Transplantation for VEXAS Syndrome: Results of a Multicenter Study of the EBMT. Blood Adv 2024; bloodadvances.2023012478.
Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454–65.
Bernard E, Tuechler H, Greenberg PL, Hasserjian RP, Arango Ossa JE, Nannya Y et al. Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. NEJM Evid 2022; 1: EVIDoa2200008.
Zhao L-P, Schell B, Sébert M, Kim R, Lemaire P, Boy M, et al. Prevalence of UBA1 mutations in MDS/CMML patients with systemic inflammatory and auto-immune disease. Leukemia. 2021;35:2731–3.
Zhao L-P, Dumas-Rivero T, Barette L, Aguinaga L, Cheffai A, Chauvel C et al. Prognostic Significance of Monocytic-like Phenotype in AML patients treated with Venetoclax and Azacytidine. Blood Adv 2025; bloodadvances.2024015734.
Gurnari C, Maciejewski JP. How I manage acquired pure red cell aplasia in adults. Blood. 2021;137:2001–9.
Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122:3616–27.
Acknowledgements
The authors thank all members of the FRENVEX group for their contribution to the development of this work.
Author information
Authors and Affiliations
Consortia
Contributions
L.-P.Z. collected the data and performed the analyses. L.-P.Z. and P.F. wrote the manuscript. O.K., L.L., and E.C. contributed to the interpretation and analysis of the genetic and phenotypic data. A.M., L.A., J.-D.B., S.A., E.C., O.F., B.T., S.G.-L., J.H., J.-D.K., O.K., L.L., G.L.G., H.L., M.H., T.C., T.M., M.S., P.F., V.J., L.T., L.-P.Z., L.W., and the members of the FRENVEX group contributed to patient care and clinical data acquisition. All authors critically reviewed and approved the final version of the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Ethical consent
Informed consent was not required as patients were managed according to standard procedures, and data were collected and analyzed retrospectively. The study was conducted in compliance with the Good Clinical Practices Protocol and the Declaration of Helsinki principles. This study received approval from Comité d’Ethique de la Recherche (CER) Paris Nord, Institutional Review Board -IRB 00006477- of HUPNVS, Paris 7 University, AP-HP (No. CER-2022-194).
Patient and public involvement
Patients were not involved in the design, conduct, reporting, or dissemination plans of this research.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Zhao, LP., Kosmider, O., Heiblig, M. et al. Characteristics and prognostic significance of myelodysplasia-related features in VEXAS syndrome. Leukemia (2026). https://doi.org/10.1038/s41375-025-02858-2
Received:
Revised:
Accepted:
Published:
Version of record:
DOI: https://doi.org/10.1038/s41375-025-02858-2
